摘要
达格列净是高度选择性的钠⁃葡萄糖协同转运蛋白2(sodium⁃dependent glucose transporters 2,SGLT⁃2)抑制剂,可作为单药用于改善2型糖尿病成人患者的血糖控制。本文从专利申请趋势、地区分布、重要申请人角度对达格列净相关专利申请情况进行统计分析,帮助研发人员了解该药物的发展趋势、研发主体以及在华保护情况,为国内相关制药企业提供技术发展和知识产权战略方面的建议。
Dapagliflozin is a highly selective sodium⁃dependent glucose transporters 2(SGLT⁃2)inhibitor,and can be used as a single agent for glycemic control in adult patients with type 2 diabetes mellitus.To help developers understand the development trends of the drug,the body of development and the protection situation in China,statistical analysis of dapagliflozin⁃related patent application scenarios is performed herein from the perspective of patent application trends,regional distribution,important applicants,in order to provide advice on technological development and intellectual property strategies to domestically relevant pharmaceutical companies.
作者
王星
WANG Xing(Reexamination and Invalidation Department of the Patent Office,China National Intellectual Property Administration,Beijing 100088,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2024年第21期2209-2213,共5页
Chinese Journal of New Drugs
